
Cardiology Fellow @laheycardiology | Former Lahey IM Chief Resident @bethisraellahey | Alum @UNECOM
Burlington, MA
Joined February 2022
- Tweets66
- Following318
- Followers145
- Likes478
Pinned Tweet
Thrilled to share our work in #JACC: CardioOnc & be presenting at #GCOS2024! #SGLT2i associated with ⬇️ risk of #CTRCD in patients with cancer and T2DM. A hopeful advance for survivorship & CardioOncology! Thankful to mentors @SarjuGanatraMD @SaurabhSDani bit.ly/4ebDU7t
Ammar Bhatti DO retweeted
Our commentary published today in American College of Cardiology acc.org describing sex specific distribution of CAC scores in South Asian Adults in the United States.
acc.org/Latest-in-Cardiology…
Describing the Sex-Specific Distribution of CAC Scores in South Asian Adults in the United States - American College of Cardiology acc.org/Latest-in-Cardiology…
Ammar Bhatti DO retweeted
Describing the Sex-Specific Distribution of CAC Scores in South Asian Adults in the United States - American College of Cardiology acc.org/Latest-in-Cardiology…
Ammar Bhatti DO retweeted
And the journey begins for these fantastic gentlemen! We welcome you @LaheyCardiology and look forward to your all round training and transformation as able cardiologists!
Ammar Bhatti DO retweeted
Takeaways from #ACC2025. Late breaking trials - take home points
@ACCinTouch
1. WARRIOR Trial : Intensive medical therapy did not significantly impact the rate of serious cardiovascular events at five years in women with suspected ischemia with nonobstructive coronary arteries (INOCA).
Ammar Bhatti DO retweeted
#SGLT2i therapy w/ #empagliflozin exerts a dose-dependent cardioprotective effect against AIC. Improved #LVEF was accompanied by enhanced ketone body consumption, improved cardiac energetics, & preserved mitochondrial structure & function jacc.org/doi/10.1016/j.jacca… #JACCCardioOnc
Ammar Bhatti DO retweeted
“Excited to share our latest editorial published in @CircAHA - Our study highlights T1 mapping as a novel marker for heart failure progression in hypertrophic cardiomyopathy (HCM).
@EthanRowin @JAHA_AHA @AHAScience
Ammar Bhatti DO retweeted
A large review on atrial fibrillation? Don’t mind if I do. Program directors should be printing this out and handing it to all applicable residents. 🎩 tip to the authors.
eddyjoemd.com/foamed
Ammar Bhatti DO retweeted
I had a fantastic time recording podcast on Heart Disease in South Asians with Rahul Menon of @DiasporaIndian. Listen to this candid but critical conversation here. Special thanks to @khurramn1 @alka_kanaya @jaideeppatelmd @AAgarwalaMD @PSatishMD @pnatarajanmd @RomitB_MD @SarjuGanatraMD @DLBHATTMD
youtu.be/nNhvzW1oBRg?si=kXio…
Ammar Bhatti DO retweeted
In this #JACCCardioOnc study, Dr. @AmmarWB, et al highlight that #SGLT2 inhibitors 📉 the risk of CTRCD in pts w/ #T2DM & cancer, as well as lower #heartfailure exacerbations, mortality, & 🏥 jacc.org/doi/10.1016/j.jacca…
#CardioOncology #SGLT2i @anita_deswal @AnaBaracCardio @JLiu_MSKCardOn @datsunian @RichardKCheng2 @TeresaLpezFdez @SumanthKhadkeMD @SarjuGanatraMD
Ammar Bhatti DO retweeted
#GLP1RA works for pts with #obesity and #HFpEF
Do they work for non-obese (BMI<30) pts with HFpEF??
✅️THEY DO
Among non-obese pts with #Diabetes & #HFpEF
GLP-1RA use improved outcomes
⏬️ 🫀failure exacerbation
⏬️ 🏨 hospitalization
⏬️💗 arrhythmia
⏬️ kidney related complications etc
sciencedirect.com/science/ar…
Study led by our brilliant research fellow @SumanthKhadkeMD in collaboration with @Ashish_Kumar_MD
@AmmarWB @SonuAbrahamMD
With the guidance from maestro of the field @SaurabhSDani @JavedButler1 @mvaduganathan
@gcfmd @anita_deswal @Sadeer_AlKindi @MkosiborodMD @khurramn1 @virani_md et al.
Ammar Bhatti DO retweeted
I am thrilled to share my podcast commentary in JACC:Cardio oncology jacc.org/do/10.1016/1f1abaeb…
Ammar Bhatti DO retweeted
Happy to share our Invited Editorial with @MohamedDabour91 @BlaesAnneMD and @DhariniRamu
SGLT2 Inhibitors in Mitigating Cancer Therapy-Related Cardiac Dysfunct... sciencedirect.com/science/ar…
Ammar Bhatti DO retweeted
Thrilled to have matched a fantastic group @LaheyCardiology for Cardiology Fellowship 2025!
@AmmarWB @BrandonTemelMD @SriramG999 @PawanDagaMD Looking forward to working with you!
Ammar Bhatti DO retweeted
New #JACCHF 📄: bit.ly/40xnSB9
In patients w/ #Obesity, #T2DM & #HFpEF➡️#GLP1 agonists provide incremental benefits in addition to #SGLT2i w/ reduction in:
🔸HF exacerbation
🔸All-cause 🏥
🔸Atrial arrhythmias
🔸AKI
🔸Pulmonary #HTN
@rushin311 @SarjuGanatraMD @LaheyResearch
Ammar Bhatti DO retweeted
A recent study by @PennThalheimer @mariellesc1 et al. sought to determine whether SGLT2i use is associated with a lower incidence of CTRCD in patients w/ #T2DM & #cancer.
Learn more 👉 spr.ly/6016qlXbM
#cardiomyopathy #cardiooncology
Ammar Bhatti DO retweeted
The highest score research abstract @ACCMass comes from @LaheyResearch @LaheyCardiology @LaheyHospital from Bhargav Makwana! Heartiest congratulations and look forward to your successful academic career with us! @SarjuGanatraMD #Microplastics #EDOH @smoffattbruce1
Ammar Bhatti DO retweeted
SGLT2 inhibition may prevent cancer therapy-related cardiac dysfunction and improve other outcomes in patients with diabetes undergoing cancer therapy #GCOS2024 @HemoncToday #CardioOncology @ACCinTouch
Read more👇
healio.com/news/cardiology/2…



















